CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 460 enrolled
Drug / intervention
Rebif® (clone 484-39)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00367484
NCT00367484Phase 4Completed
CompareCT.gov

Multicentre, Single Arm, Open, Phase IV Study To Evaluate Immunogenicity And Safety Of Subcutaneous r-hIFN Beta-1a (Rebif®) Using Clone 484-39 In The Treatment Of Relapsing Remitting Multiple Sclerosis

Merck KGaA, Darmstadt, Germany·interventional·Posted Aug 23, 2006·Updated Feb 27, 2014

In Brief

A Phase 4 clinical trial evaluating Rebif® (clone 484-39) for Relapsing Remitting Multiple Sclerosis. Completed, enrolled 460 participants.

Detailed Summary

The objectives of the study are: \- comparison of the incidence and time course of the development of neutralizing antibodies (NAbs) to Rebif after 48 weeks of therapy, to historical data from Serono clinical trial databases to assess the safety and tolerability of Rebif®

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Remitting Multiple Sclerosis
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 23, 2006
Enrollment StartMay 1, 2004
Primary CompletionJan 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 19.9 years ago

Interventions

Rebif® (clone 484-39)biological

s.c. administered Rebif®